BioCryst Pharmaceuticals Inc
BCRX8.305USD
+0.355+4.47%
Horário de mercado （ET）Cotações atrasadas em 15 min
1.74BValor de mercado
PerdaP/L TTM
Mais detalhes de BioCryst Pharmaceuticals Inc Empresa
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with complement-mediated and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.
Informações da empresa
Código da empresaBCRX
Nome da EmpresaBioCryst Pharmaceuticals Inc
Data de listagemMar 04, 1994
CEOMr. Charles K. Gayer
Número de funcionários580
Tipo de títulosOrdinary Share
Fim do ano fiscalMar 04
Endereço4505 Emperor Blvd Ste 200
CidadeDURHAM
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal27703-8457
Telefone19198591302
Sitehttps://www.biocryst.com/
Código da empresaBCRX
Data de listagemMar 04, 1994
CEOMr. Charles K. Gayer
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Jon P. Stonehouse
Mr. Jon P. Stonehouse
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
939.88K
-20.60%
Mr. Charles K. Gayer
Mr. Charles K. Gayer
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
237.81K
-26.43%
Ms. Alane P. Barnes
Ms. Alane P. Barnes
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
215.03K
-26.71%
Dr. Helen M. Thackray, M.D.
Dr. Helen M. Thackray, M.D.
Chief Research & Development Officer
Chief Research & Development Officer
161.62K
-26.06%
Mr. Babar Ghias
Mr. Babar Ghias
Chief Financial Officer, Head of Corporate Development
Chief Financial Officer, Head of Corporate Development
147.00K
--
Dr. Nancy J. Hutson, Ph.D.
Dr. Nancy J. Hutson, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
99.14K
+14.43%
Mr. Vincent J. Milano
Mr. Vincent J. Milano
Independent Director
Independent Director
89.76K
+16.18%
Dr. Steven K. Galson, M.D.
Dr. Steven K. Galson, M.D.
Independent Director
Independent Director
70.87K
+21.41%
Mr. Alan G. Levin
Mr. Alan G. Levin
Independent Director
Independent Director
64.27K
+24.14%
Dr. Amy E. Mckee, M.D.
Dr. Amy E. Mckee, M.D.
Independent Director
Independent Director
40.33K
+44.91%
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Jon P. Stonehouse
Mr. Jon P. Stonehouse
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
939.88K
-20.60%
Mr. Charles K. Gayer
Mr. Charles K. Gayer
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
237.81K
-26.43%
Ms. Alane P. Barnes
Ms. Alane P. Barnes
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
215.03K
-26.71%
Dr. Helen M. Thackray, M.D.
Dr. Helen M. Thackray, M.D.
Chief Research & Development Officer
Chief Research & Development Officer
161.62K
-26.06%
Mr. Babar Ghias
Mr. Babar Ghias
Chief Financial Officer, Head of Corporate Development
Chief Financial Officer, Head of Corporate Development
147.00K
--
Dr. Nancy J. Hutson, Ph.D.
Dr. Nancy J. Hutson, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
99.14K
+14.43%
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 12 de jul
Atualizado em: sáb, 12 de jul
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
10.33%
BlackRock Institutional Trust Company, N.A.
8.55%
Kynam Capital Management LP
4.27%
Avoro Capital Advisors LLC
4.16%
State Street Global Advisors (US)
3.73%
Other
68.96%
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
10.33%
BlackRock Institutional Trust Company, N.A.
8.55%
Kynam Capital Management LP
4.27%
Avoro Capital Advisors LLC
4.16%
State Street Global Advisors (US)
3.73%
Other
68.96%
Tipos de investidores
Investidores
Proporção
Investment Advisor
32.45%
Investment Advisor/Hedge Fund
29.96%
Hedge Fund
18.97%
Research Firm
3.20%
Private Equity
1.84%
Individual Investor
1.27%
Pension Fund
0.53%
Bank and Trust
0.41%
Sovereign Wealth Fund
0.25%
Other
11.14%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
549
185.97M
88.87%
-12.50M
2025Q1
560
182.40M
87.18%
-20.97M
2024Q4
556
172.66M
82.64%
-37.08M
2024Q3
554
179.19M
86.60%
-34.24M
2024Q2
532
180.82M
87.59%
-35.90M
2024Q1
546
187.78M
91.10%
-27.21M
2023Q4
549
183.67M
89.35%
-28.91M
2023Q3
542
183.90M
96.89%
-26.67M
2023Q2
545
181.25M
95.65%
-20.15M
2023Q1
554
177.87M
94.17%
-5.12M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
The Vanguard Group, Inc.
21.61M
10.33%
-230.66K
-1.06%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
17.89M
8.55%
+189.84K
+1.07%
Mar 31, 2025
Kynam Capital Management LP
8.93M
4.27%
-156.84K
-1.73%
Mar 31, 2025
Avoro Capital Advisors LLC
8.70M
4.16%
-3.17M
-26.68%
Mar 31, 2025
State Street Global Advisors (US)
7.81M
3.73%
+314.44K
+4.19%
Mar 31, 2025
Alkeon Capital Management LLC
6.00M
2.87%
+109.73K
+1.86%
Mar 31, 2025
Two Sigma Investments, LP
5.27M
2.52%
+992.22K
+23.22%
Mar 31, 2025
Deerfield Management Company, L.P.
5.19M
2.48%
-2.95M
-36.28%
Mar 31, 2025
Geode Capital Management, L.L.C.
4.96M
2.37%
+136.90K
+2.84%
Mar 31, 2025
RP Management, LLC
3.85M
1.84%
--
--
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
iShares Genomics Immunology and Healthcare ETF
3.3%
Invesco Biotechnology & Genome ETF
2.21%
Invesco Dorsey Wright Healthcare Momentum ETF
1.83%
Virtus LifeSci Biotech Products ETF
1.66%
ALPS Medical Breakthroughs ETF
1.27%
SPDR S&P Biotech ETF
0.68%
First Trust Small Cap Growth AlphaDEX Fund
0.66%
Main Thematic Innovation ETF
0.58%
Direxion Daily S&P Biotech Bull 3X Shares
0.39%
Invesco NASDAQ Future Gen 200 ETF
0.38%
Ver Mais
iShares Genomics Immunology and Healthcare ETF
Proporção3.3%
Invesco Biotechnology & Genome ETF
Proporção2.21%
Invesco Dorsey Wright Healthcare Momentum ETF
Proporção1.83%
Virtus LifeSci Biotech Products ETF
Proporção1.66%
ALPS Medical Breakthroughs ETF
Proporção1.27%
SPDR S&P Biotech ETF
Proporção0.68%
First Trust Small Cap Growth AlphaDEX Fund
Proporção0.66%
Main Thematic Innovation ETF
Proporção0.58%
Direxion Daily S&P Biotech Bull 3X Shares
Proporção0.39%
Invesco NASDAQ Future Gen 200 ETF
Proporção0.38%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
